Interferons Market Report 2025

This Interferons market report provides a comprehensive analysis of the market’s characteristics, size, and growth, including segmentation, regional and country-level breakdowns, competitive landscape, market shares, trends, and strategies. It also tracks historical and forecasted market growth across various geographies.

The interferons market size has grown steadily in recent years. It will grow from $9.17 billion in 2024 to $9.54 billion in 2025 at a compound annual growth rate (CAGR) of 4%. The growth in the historic period can be attributed to viral infections, antiviral therapies, cancer treatment, and autoimmune diseases.

The interferons market size is expected to see strong growth in the next few years. It will grow to $11.98 billion in 2029 at a compound annual growth rate (CAGR) of 5.9%. The growth in the forecast period can be attributed to immunotherapy advancements, precision medicine, viral outbreak preparedness, drug combinations, and gene therapy. Major trends in the forecast period include expanding applications, biopharmaceutical innovation, interferon combinations, and personalized medicine.

The surge in cancer cases is anticipated to fuel the growth of the interferon market. Cancer, characterized by abnormal cell growth and potential spread, finds treatment in interferons. These agents, used across various cancer types like melanoma, Kaposi's sarcoma, and certain leukemias, bolster the body's immune response against cancer cells. As per a January 2022 report from the American Cancer Society, an estimated 1.9 million new cancer cases and 609,360 anticipated cancer-related deaths are expected in the US for 2022. This includes projections for pediatric and teenage cancer cases, driving the expansion of the interferon market.

The global market for interferon drugs is poised for rapid growth due to the rising incidence of chronic diseases such as hepatitis-B, hepatitis-C, cancer, and multiple sclerosis. Interferons are instrumental in combinational therapies and advancements in drug delivery systems. Innovations in treating diseases like hepatitis-C involve combining interferon-alpha with other drugs, yielding significant virologic improvements. However, the poor gastrointestinal stability of interferon-alpha necessitates parenteral administration, leading to severe side effects. Studies indicate that nanoencapsulation within nanoparticles could enhance oral bioavailability. These trends in combinational therapies and novel drug delivery systems are expected to drive the interferon market, with ongoing exploration for COVID-19 treatment applications.

Biologics therapy, expensive and financially burdensome for healthcare systems, has prompted a closer look at biosimilars. Increasing disease prevalence has led local pharmaceutical companies to produce interferon biosimilar medications as cost-effective alternatives to original brands. Initially explored as antivirals, interferons are now pivotal in anti-HBV and anti-HCV therapy. The therapeutic promise of interferon biosimilars for hepatitis and cancer, alongside ongoing studies for prophylactic or therapeutic effectiveness against SARS, influenza, or other virus pandemics, fuels the adoption of interferon biosimilars over costly biologics.

Major companies in the interferon market are introducing innovative programs, including ADAR1 inhibitors and DHX9 inhibitors, aimed at inducing replication stress and cell death in microsatellite unstable tumors. ADAR1 inhibitors work by targeting and inhibiting ADAR1, a protein associated with immune activation in cancer cells. The inhibition of ADAR1 has been shown to lead to cell death in cells exhibiting high levels of type I interferon signaling. On the other hand, DHX9 inhibitors consist of small-molecule inhibitors that target DHX9, an RNA helicase that plays a crucial role in maintaining genomic stability in cancer. By inhibiting DHX9, these compounds can induce replication stress and cell death in certain tumor types. For example, in October 2023, Accent Therapeutics, a biopharmaceutical company based in the U.S., launched its XRN1 program. This program focuses on developing small molecule inhibitors that target the enzyme XRN1, which is vital for RNA degradation and is involved in innate immunity. The initiative aims to address tumors with heightened interferon signaling, potentially increasing cancer cell death. As part of Accent Therapeutics' commitment to developing precision cancer therapies, recent presentations at the 35th AACR-NCI-EORTC Symposium highlighted preclinical validations and advancements in the creation of selective inhibitors for this critical oncology target.

In May 2024, CytomX Therapeutics Inc. entered into a partnership with Merck & Co., Inc. for an undisclosed amount. The collaboration is focused on the development of innovative antibody-drug conjugates, with the goal of enhancing efficacy and safety in cancer treatments. Merck & Co., Inc., based in the U.S., specializes in the research, development, manufacturing, and marketing of a diverse array of medications and vaccines for various health conditions.

Interferons are natural substances that bolster the body's immune system in combating illnesses, including cancer. They are produced by white blood cells and other cells in the body, and can also be manufactured in laboratories for treating various disorders.

The primary types of interferons include interferon alpha, interferon beta, and interferon gamma. Interferon alpha is a cytokine created by the innate immune system as a response to various environmental exposures, such as viral infections. These products are distributed through hospital pharmacies, online pharmacies, retail pharmacies, and other channels, and they are utilized in treating conditions like hepatitis B, hepatitis C, melanoma, leukemia, multiple sclerosis, and renal cell carcinoma.

The interferons market research report is one of a series of new reports that provides interferons market statistics, including the interferons industry's global market size, regional shares, competitors with an interferons market share, detailed interferons market segments, market trends, and opportunities, and any further data you may need to thrive in the interferons industry. This interferons market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

Major companies operating in the interferons market include Roche Holding AG, Merck & Co. Inc., Bristol-Myers Squibb Company, Biogen Inc., Bayer AG, Zydus Cadila Health Care Limited, Novartis AG, Pfizer Inc., Biosidus S.A., Nanogen Biopharmaceutical Co. Ltd., Amega Biotech Inc., Rhein Minapharm Biogenetics S.A.E., PROBIOMED S.A. de C.V., Schering-Plough Corporation, 3SBio Inc., AbbVie Inc., Celgene Corporation, Eli Lilly and Company, Genentech Inc., GlaxoSmithKline plc, Johnson & Johnson, Novo Nordisk A/S, Sanofi S.A., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Biocad, Cipla Limited, Dr. Reddy's Laboratories Ltd., Hetero Drugs Limited.

North America was the largest region in the interferons market in 2024. Middle East is expected to be the fastest-growing region in the interferons market during the forecast period. The regions covered in the interferons market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the interferons market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The interferons market consists of sales of polypeptides, cytokine, and cell-surface receptors. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.